Gabelli Upgrades Boston Scientific (BSX) to Buy
More News related to BSX
- Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan
- Boston Scientific (BSX) Announces Agreement with DoJ on Investigation of Guidant; Updates FY09 Outlook
- Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant
- Relator's Attorneys Comment On AtriCure/DOJ Proposed Settlement
- Video: Boston Scientific Announces European Approval and Launch of Platinum Chromium PROMUS(R) Element(TM) Stent System
More News related to Upgrades
- Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
- Vascular Solutions (VASC) Receives 501(k) Clearance from U.S. FDA for GuideLiner Catheter
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- Compugen (CGEN) Announces Discovery of Biomarker CGEN-40001 for Type 2 Diabetes
Gabelli upgrades Boston Scientific (NYSE: BSX) from Hold to Buy.
Shares of Boston Scientific are trading higher today amid the Gabelli upgrade and increased earnings estimates at JPMorgan. The stock most recently traded at $10.34, up 3.4% from yesterday's closing price.
To see all the analyst calls on Boston Scientific, visit our Analyst Ratings page.
Boston Scientific Corporation operates as a developer, manufacturer, and marketer of medical devices used in various interventional medical specialties worldwide.
Related Categories
UpgradesStocks Mentioned
+0.10Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
